Oragenics, Inc. Management Update Webinar on May 20, 2025: Key Discussion Points

Oragenics, Inc. will be hosting a management update webinar on May 20, 2025, to dive into the landscape of concussion treatment and discuss their ONP-002 clinical program. This event will provide a strategic vision and insights from key players in the company.

Scheduled for 4:00 PM ET, the webinar will feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly. They will share valuable information and answer live questions from attendees.

Concussion treatment is an area with significant unmet medical needs, especially in sports and civilian trauma. Oragenics aims to address this gap with ONP-002, a unique neuroprotective therapy designed for mild traumatic brain injury, also known as concussion.

Enabling non-invasive direct brain delivery while minimizing systemic exposure, ONP-002 has shown promise in preclinical studies by reducing inflammation, oxidative stress, and brain swelling post head injury. The compound has also passed Phase I trials safely, marking it as a potential game-changer in the treatment of concussions.

For those interested in learning more about Oragenics and their developments, the live webcast and replay will be available on their Investor Relations page at the specified date and time. This biotechnology company is dedicated to revolutionizing intranasal therapeutics for neurological disorders, with a special focus on mTBI treatment and advanced drug delivery methods.

If you want to stay up to date with Oragenics, make sure to mark your calendars for this informative webinar. It’s a chance to gain valuable insights into the future of concussion treatment and the innovative approaches being taken by Oragenics to meet this critical medical need.